This afternoon we watched Ascendis Pharma A/S drop -10.6% to a price of $120.46 per share. The Mid-Cap Pharmaceutical company is now trading -38.1% below its average target price of $194.6. Analysts have set target prices ranging from $164.21 to $275.68 per share for Ascendis Pharma A/S, and have given the stock an average rating of buy.
The stock has an above average percentage of its shares sold short at 9.3%, and a short ratio of 9.69. Only 0.76% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 107.9% of Ascendis Pharma A/S's shares being owned by this investor type.
Institutions Invested in Ascendis Pharma A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | RA Capital Management, L.P. | 17% | 10,108,400 | $1,217,657,854 |
| 2024-06-30 | Westfield Capital Management Co LP | 9% | 4,962,824 | $597,821,774 |
| 2024-06-30 | FMR, LLC | 8% | 4,922,555 | $592,970,970 |
| 2024-06-30 | Artisan Partners Limited Partnership | 7% | 4,295,029 | $517,379,189 |
| 2024-06-30 | Avoro Capital Advisors LLC | 7% | 4,196,661 | $505,529,780 |
| 2024-06-30 | Janus Henderson Group PLC | 7% | 3,918,813 | $472,060,210 |
| 2024-06-30 | Wellington Management Group, LLP | 4% | 2,612,856 | $314,744,631 |
| 2024-06-30 | Capital International Investors | 4% | 2,104,298 | $253,483,735 |
| 2024-06-30 | Franklin Resources, Inc. | 4% | 2,084,851 | $251,141,149 |
| 2024-06-30 | Price (T.Rowe) Associates Inc | 3% | 1,784,148 | $214,918,466 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Ascendis Pharma A/S.
